CU20220035A7 - Anticuerpos anti-glicoproteína ib alfa humanizada (gpibalpha) - Google Patents

Anticuerpos anti-glicoproteína ib alfa humanizada (gpibalpha)

Info

Publication number
CU20220035A7
CU20220035A7 CU2022000035A CU20220035A CU20220035A7 CU 20220035 A7 CU20220035 A7 CU 20220035A7 CU 2022000035 A CU2022000035 A CU 2022000035A CU 20220035 A CU20220035 A CU 20220035A CU 20220035 A7 CU20220035 A7 CU 20220035A7
Authority
CU
Cuba
Prior art keywords
humanized antibodies
platelet
antibodies
humanized
lack
Prior art date
Application number
CU2022000035A
Other languages
English (en)
Inventor
Heyu Ni
Original Assignee
Ccoa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ccoa Therapeutics Inc filed Critical Ccoa Therapeutics Inc
Publication of CU20220035A7 publication Critical patent/CU20220035A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>La presente invención se refiere a anticuerpos polivalentes de glucoproteína anti-plaquetarios 1 (b)αlfa que pueden causar efectos secundarios graves. La presente descripción proporciona anticuerpos humanizados que reconocen específicamente la glicoproteína 1 (b)αlfa y que carecen de una porción Fc, por lo que no interaccionan con el receptor Fc. Los anticuerpos humanizados son capaces de prevenir la activación y agregación plaquetaria, y reducir el tamaño/crecimiento del trombo y prevenir la oclusión de los vasos. También pueden ser muy útiles para disminuir la interacción plaquetas- células tumorales y disminuir la metástasis tumoral. A dosis terapéuticas, los anticuerpos humanizados carecen de la capacidad de inducir la activación de plaquetas, inducir trombocitopenia; y/o prolongar el tiempo de sangrado.</p>
CU2022000035A 2019-12-10 2020-12-10 Anticuerpos anti-glicoproteína ib alfa humanizada (gpibalpha) CU20220035A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962946086P 2019-12-10 2019-12-10
PCT/CA2020/051699 WO2021113974A1 (en) 2019-12-10 2020-12-10 Humanized anti-glycoprotein ib alpha (gpibalpha) antibodies

Publications (1)

Publication Number Publication Date
CU20220035A7 true CU20220035A7 (es) 2023-01-16

Family

ID=74971870

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000035A CU20220035A7 (es) 2019-12-10 2020-12-10 Anticuerpos anti-glicoproteína ib alfa humanizada (gpibalpha)

Country Status (17)

Country Link
US (1) US20230022143A1 (es)
EP (1) EP4073123A4 (es)
JP (2) JP2023506772A (es)
KR (1) KR20220127250A (es)
CN (1) CN112500483B (es)
AU (1) AU2020399790A1 (es)
BR (1) BR112022011226A2 (es)
CA (1) CA3159975A1 (es)
CL (1) CL2022001504A1 (es)
CO (1) CO2022008680A2 (es)
CU (1) CU20220035A7 (es)
IL (1) IL293736A (es)
MX (1) MX2022007118A (es)
PE (1) PE20221325A1 (es)
TW (1) TWI786485B (es)
WO (1) WO2021113974A1 (es)
ZA (1) ZA202207325B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113264995A (zh) * 2021-05-26 2021-08-17 苏州大学 一种血小板GPIbα蛋白相关的抗原表位肽及其应用
WO2023007182A1 (en) * 2021-07-29 2023-02-02 The University Of Birmingham Protein interaction inhibitors
CN113663822B (zh) * 2021-08-20 2023-12-05 中国人民解放军陆军军医大学第一附属医院 一种富血小板纤维蛋白凝胶的分离方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL137121A0 (en) * 1998-10-30 2001-06-14 Miller Jonathan L Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha
GB9918788D0 (en) * 1999-08-10 1999-10-13 Leuven K U Res & Dev Antithrombotic effect of platelet glycoprotein 1b blocking monoclonal Fab fragments
EP2186829B1 (en) * 2008-11-14 2014-12-31 Canadian Blood Services Antibodies against GPIbalpha
CN102988983B (zh) * 2011-09-09 2014-06-11 苏州苏大赛尔免疫生物技术有限公司 抗人血小板膜糖蛋白Ibα嵌合抗体药物组合物
CN107082809B (zh) * 2017-06-13 2020-11-10 华东理工大学 靶向血小板膜糖蛋白GPIbα的抑制肿瘤转移的单克隆抗体及其筛选方法

Also Published As

Publication number Publication date
CA3159975A1 (en) 2021-06-17
CN112500483B (zh) 2022-11-29
AU2020399790A1 (en) 2022-07-14
EP4073123A1 (en) 2022-10-19
IL293736A (en) 2022-08-01
CN112500483A (zh) 2021-03-16
CO2022008680A2 (es) 2022-06-30
PE20221325A1 (es) 2022-09-09
CL2022001504A1 (es) 2023-02-03
MX2022007118A (es) 2022-10-03
JP2023506772A (ja) 2023-02-20
KR20220127250A (ko) 2022-09-19
WO2021113974A1 (en) 2021-06-17
EP4073123A4 (en) 2024-01-10
BR112022011226A2 (pt) 2022-08-30
ZA202207325B (en) 2022-08-31
US20230022143A1 (en) 2023-01-26
TW202123972A (zh) 2021-07-01
JP2024123243A (ja) 2024-09-10
TWI786485B (zh) 2022-12-11

Similar Documents

Publication Publication Date Title
CU20220035A7 (es) Anticuerpos anti-glicoproteína ib alfa humanizada (gpibalpha)
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
CO2022006105A2 (es) Compuesto de péptidos cíclicos que tiene acción inhibidora de kras
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CO2018002265A2 (es) Anticuerpos anti-cd19 humano humanizados
CL2022001375A1 (es) Receptores de antígeno quimérico cd19 y cd22 y usos de los mismos
EA201991607A1 (ru) Генетически модифицированные клетки-натуральные киллеры
PE20200757A1 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
PE20161389A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CO2021004560A2 (es) Anticuerpos estabilizadores de trem2
CR20180554A (es) Preparaciones que contienen anticuerpos
CO2019012568A2 (es) Virus de la enfermedad de newcastle y usos de los mismos
PE20180556A1 (es) Anticuerpos inhibidores via del factor tisular y usos de los mismos
ECSP19062769A (es) Formulación de anticuerpo monoclonal anti-vrs
CO2019005909A2 (es) Anticuerpos y polipéptidos dirigidos contra cd127
PE20191079A1 (es) Inmunoglobulinas y usos de estas
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
CL2019002854A1 (es) Compuesto macrocíclico y sus usos.
CL2021001537A1 (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
EA201991918A1 (ru) Самосборные белковые наночастицы со встроенными белками с шестиспиральным пучком
AR116141A1 (es) CATALIZADOR QUE CONTIENE Ni PARA LA OLIGOMERIZACIÓN DE OLEFINAS
BR112021020843A2 (pt) Conjunto de polipeptídeos precursores heterodiméricos, polipeptídeos heterodiméricos, métodos para gerar um polipeptídeo heterodimérico e para identificar um polipeptídeo heterodimérico multiespecífico, polipeptídeo heterodimérico multiespecífico, primeiro e segundo polipeptídeo precursor heterodimérico
PE20190966A1 (es) Factor viii direccionado a los globulos rojos y metodo para su uso
AR106874A1 (es) Compuestos 1,3,4-tiadiazol y su uso en el tratamiento de cáncer
CL2022000193A1 (es) Composición de vacuna y sus usos para el control o la prevención de una infestación por piojos de mar (divisional de la solicitud no. 201900422)